Consumption of the Putative Chemopreventive Agent Curcumin by Cancer Patients: Assessment of Curcumin Levels in the Colorectum and their Pharmacodynamic Consequences

 

Cancer Epidemiol Biomarkers Prev. 2005; 14(1):120-25.

 

Curcumin in animal models has shown to reduce the levels of oxidative DNA adduct M1G and expression of COX-2 enzyme.

 

Objective:

To test the hypothesis that pharmacologically active levels of Curcumin can be achieved in colorectum tissue of humans by oral consumption to effect the levels of M1G and COX-2 proteins.

 

Study Design:

12 subjects suffering from colorectal carcinoma with tumor location in ascending / transverse colon, sigmoid and rectal colon were recruited. The subjects were divided in three groups of 4 per group and administered Curcumin C3 Complex® in the form of capsule of 450 mg each. The three groups were given doses of 1, 4 or 8 capsules per day, translating to 450, 1800 or 3600 mg of Curcumin daily, for 7 days before surgery. The Curcumin and its conjugates were analyzed in tissue and plasma as well as the levels of COX-2 proteins and M1G adducts were analyzed in colorectal tissue.

 

Results:

  • Levels of Curcumin in normal and malignant colorectal tissue ranged from 7 to 20 nmol/g tissue.
  • In patients receiving 1.8 or 3.6 g Curcumin, the concentration of Curcumin measured was 21.7±8.2 and 6.8±3.7 nmol/g in right and left colon respectively.
  • Colorectal mucosa of 7 out of 8 patients who received 1.8 g or 3.6 g of Curcumin exhibited Curcumin sulphate and 2 patients on highest dose exhibited Curcumin glucuronide.
  • Researchers were not able to detect the reduced metabolites such as hexahydrocurcumin and hexahydrocurcuminol in the intestinal tissue.
  • Administration of Curcumin did not affect the M1G levels in normal colorectal mucosa while it caused a decrease in adduct levels in malignant colorectal mucosa. 

 

Conclusion:

Based on the results obtained, the authors were able to conclude that a dose of 1.8 g of Curcumin might actually have achieved the statistically significant reduction of M1G levels. Study also shows that a dosage of 3.6 g is safe in humans and negative targeting of Curcumin could be a considerable advantage. Further, concentrations of Curcumin achieved in colorectal mucosa are consistent with levels needed to exert chemopreventive activity.

 

About Sabinsa

Sabinsa Corporation is a manufacturer, supplier and marketer of herbal extracts, cosmeceuticals, minerals, dietary supplements and specialty fine chemicals for the nutritional, cosmetic, pharmaceutical and food industries.

Read More..

HeadQuarters

Sabinsa Corporation

20 Lake Drive 

East Windsor,

NJ 08520, USA

Tel: +1 732 777 1111

Fax: +1 732 777 1443

This email address is being protected from spambots. You need JavaScript enabled to view it.

 

Contact Presence